RAD51C and neoplasm: On further investigation, none of the heterozygous cases showed evidence of promoter hyper-methylation or somatic point mutations in RAD51C. Of the eight tumours from heterozygous carriers of the p.Gly264Ser allele, only four showed copy number loss with three of these involving loss of the variant allele.